Progress for Johnson & Johnson's lung cancer drug as extension submitted to EMA

2 years ago 69

The Janssen Pharmaceutical Companies of Johnson & Johnson announced last week (November 23) the submission of a type 2 extension of indication application to the European Medicines Agency (EMA).

1. Homepage
2. Prostate Cancer
3. Progress for Johnson & Johnson's lung cancer drug as extension submitted to EMA